Abnormal sialylation due to overexpression of sialyltransferases has been associated with tumorigenesis and tumor progression. Although ST6Gal-I influences cancer persistence and progression by affecting various receptors, the underlying mechanisms and mediators remain largely obscure, especially in hepatocellular carcinoma (HCC). We found that ST6Gal-I expression was markedly upregulated in HCC tissues and cells, high levels being associated with aggressive phenotype and poor prognosis. Furthermore, we examined the roles and mechanisms of ST6Gal-I in HCC tumorigenesis and metastasis in vitro and in vivo. ST6Gal-I overexpression promoted proliferation, migration and invasion of Huh-7 cells, whereas its knockdown restricted these abilities in MHCC97-H cells. Additionally, in a mouse xenograft model, ST6Gal-I-knockdown MHCC97-H cells formed significantly smaller tumors, implying that ST6Gal-I overexpression can induce HCC cell malignant transformation. Importantly, enhanced HCC tumorigenesis and metastasis by ST6Gal-I may be associated with Wnt/β-catenin signaling promotion, including β-catenin nuclear transition and upregulation of downstream molecules. Together, our results suggest a role for ST6Gal-I in promoting the growth and invasion of HCC cells through the modulation of Wnt/β-catenin signaling molecules, and that ST6Gal-I might be a promising marker for prognosis and therapy of HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most frequently diagnosed malignant tumor and the second leading cause of growing life-threatening cancer worldwide. 1 The close correlation between its incidence and the number of deaths attributed to this cancer indicate its high fatality rate. Approximately 80-90% of cases occur in Asia and Africa, and in China, the large majority of which are associated with chronic hepatitis B virus infection. 2, 3 Currently, most of HCC patients cannot be diagnosed in the early stage and they therefore lost the best opportunity for treatment. 4, 5 Despite tremendous advances in early diagnosis and surgery, HCC incidence continues to increase worldwide. Demonstrations of the efficacy of targeted molecular therapies have triggered the search for additional molecules capable of improving patient survival.
Glycosylation is a post-translational modification that affects protein folding, stability and activity, and plays important roles in many biological and pathological processes such as immune recognition and tumor progression. 6, 7 In cancer cells, normal glycosylation is altered 8 by various causes such as glycosyltransferase dysregulation, changes in the tertiary conformation of the peptide backbone, and alterations of sugar nucleotide donors and cofactors. 9, 10 Dall'olio F et al. 11 reported that the expression of glycosyltransferase can be regulated by the genetic and epigenetic changes. Abnormal sialylation is a distinctive feature of tumor cells associated with malignant phenotypes including invasiveness and metastatic potential. 12, 13 For example, gastric and colorectal cancers present high levels of sialyl-Lewis A (SLe A ) and sialyl-Lewis X (SLe X ) as terminal epitopes of protein O-glycans, N-glycans and glycolipids. 14 There are 20 sialyltransferases to be identified, and they were divided into β-galactoside α2,3-sialyltransferases (ST3GalI-VI), β-galactoside α2,6-sialyltransferases (ST6Gal-I and II), GalNAc α2,6-sialyltransferases (ST6Gal-NAcI-VI) and α2,8-sialyltransferases (ST8SIAI-VI) families. 15 It has been reported that the high expression of ST6Gal-I increases in the levels of α2,6-sialylation, and correlates with tumorigenesis and tumor progression. [16] [17] [18] Lu et al. 19 showed that α2,6-sialylated glycans can promote the malignant phenotypes of many tumors by regulating the related signaling pathways. ST6Gal-I is known to regulate the interaction between galectin-1 and α2,6-sialylated N-glycans, and further prevents angiogenesis and tumor progression. 17, 20, 21 The Rabinovich lab showed that ST6Gal-I overexpression increased in the α2,6-sialylation levels of glycoproteins, and inhibited the binding of galectin-1 and promoted the cellular apoptosis. 22, 23 In our previous study, we found that upregulation of ST6Gal-I increased the adhesive capability of mouse hepatocarcinoma cell to lymph node. 24 However, the predictive and prognostic values of ST6Gal-I and its effect on HCC progression remained unclear.
In this study, we aimed to unravel the functions and mechanisms of ST6Gal-I in modulating the growth in vitro and in vivo of HCC. Moreover, its association with HCC clinical characteristics and the potential underlying mechanisms were explored. Surprisingly, examination of ST6Gal-I levels in HCC and paired normal samples revealed high expression in the former
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and a close correlation with survival rate. We found that ST6Gal-I upregulation promoted the proliferation, migration and invasion ability of HCC cells. Furthermore, of the pathways tested, ST6Gal-I had the largest influence on Wnt/β-catenin signaling. Therefore, ST6Gal-I might be a promising marker for prognosis and therapy of HCC.
RESULTS

ST6Gal-I expression is significantly upregulated in HCC tissues and cell lines
To explore the role of ST6Gal-I in HCC development, ST6Gal-I was stained by immunohistochemistry (IHC) in representative pairs of cancerous and matched non-tumor liver sections from HCC patients ( Figure 1a ). Pearson's chi-squared test identified a significant correlation between ST6Gal-I expression with patient sex, number of lesions and pathologic grade ( Table 1 ). We found that ST6Gal-Ipositive patients experienced poorer 5-year overall survival than ST6Gal-I-negative patients (Figure 1b ). Moreover, ST6Gal-I positive expression was found to correlate with a short disease-free survival time ( Figure 1c ). The results are consistent with ST6Gal-I being a potential biomarker of carcinoma progression. 25, 26 In HCC and normal liver cell lines, ST6Gal-I was expressed in all tested cells as indicated by qPCR and western blot assays. The highest expression was observed in MHCC97-H cells, compared to which Huh-7 cells exhibited low expression ( Figures 1d and e ). ST6Gal-I expression and localization were confirmed by confocal microscopy, and the results revealed low ST6Gal-I expression in the latter, but high expression in the Golgi apparatus of the former (Figure 1f ).
ST6Gal-I overexpression promotes Huh-7 cell proliferation, invasion and migration in vitro
To investigate its function in HCC, ST6Gal-I was overexpressed by transfecting Huh-7 cells with the recombinant vector pcDNA3.1/ST6Gal-I. Expression of ST6Gal-I at mRNA and protein levels was increased in these cells compared to those transfected with an empty pcDNA3.1 plasmid (mock) and parental cells (Huh-7) (Figures 2a and b ). Immunofluorescence demonstrated that compared to the control treatment, overexpression of ST6Gal-I increased its presence in the Golgi apparatus of Huh-7 cells ( Figure 2d ). In addition, ST6Gal-I overexpression resulted in a significant increase in α2,6-sialylation on Huh-7 cell surface (Figures 2c and e ). CCK-8 assay showed that at 24, 48, 72 and 96 h after transfection, ST6Gal-I significantly enhanced cell growth rate ( Figure 2f ). Cancer cell growth was also assessed by colony formation assay. Huh-7 cells overexpressing ST6Gal-I formed significantly more colonies than control cells ( Figure 2g ). Accordingly, ST6Gal-I overexpression in Huh-7 cells triggered cell cycle arrest in S phase and a reduction in the number of cells in G0/G1 ( Figure 2h ). Moreover, the wound closure ability of Huh-7/ST6Gal-I cells was remarkably higher than that of control cells after 0, 4, 8 and 12 h ( Figure 2i ). Using Transwell/Matrigel assays, we found that in vitro, the mobility and invasiveness were dramatically increased in ST6Gal-I-overexpressing cells as compared to control groups (Figures 2j and k) . Taken together, these findings suggest that ST6Gal-I functions as an oncogene by promoting cancer cell proliferation. Figure 3f ). Accordingly, in an evaluation of the effects of ST6Gal-I knockdown on clonogenic capacity, colony formation was found to be reduced by shST6Gal-I knockdown ( Figure 3g ). Scratch assays showed that decreased ST6Gal-I expression significantly attenuated MHCC97-H cell migration ( Figure 3i ). The proportion of ST6Gal-I knockdown cells in S phase was smaller than that in negative control groups, and lower than the percentage arrested at G1/S (Figure 3h ). Correspondingly, measurement of cell motility by Transwell/ Matrigel assay revealed that suppression of ST6Gal-I restricted migration of MHCC97-H/shST6Gal-I cells (Figures 3j and k) . These findings suggest that ST6Gal-I expression is positively correlated with the proliferation, migration and invasion potential of HCC cells.
ST6Gal-I knockdown attenuates MHCC97-H cell proliferation, invasion and migration in vitro
Roles and expression of ST6Gal-I in liver tumorigenicity in mice
To examine the effect of ST6Gal-I on tumorigenesis in vivo, nude mice were inoculated with ST6Gal-I-knockdown or control cells. Both tumor size and growth rate were dramatically decreased in the MHCC97-H/shST6Gal-I group (Figures 4a and b ). In addition, tumor weights were markedly lower in this group (Figure 4c ). The average tumor volume at the injection site 4 weeks after inoculation of ST6Gal-I-knockdown cells was obviously smaller than that in the control group (Figure 4d 
ST6Gal-I overexpression augments Wnt signaling pathways in HCC cells
To explore the possible mechanisms underlying the effects of ST6Gal-I on the malignant behaviors of HCC cells, we analyzed the PI3K/Akt, MAPK and Wnt/β-catenin signaling pathways. The results showed that the expression of p-GSK-3β, β-catenin, Cyclin D1, c-Myc, TCF1 and TCF4 was significantly higher in Huh-7/ST6Gal-I cells than in control cells, while the expression of p-β-catenin and GSK-3β proteins was not changed (Figures 5a and b ). Additionally, there were no apparent differences in the expression levels of Erk1/2, p-Erk1/2, JNK and p-JNK in ST6Gal-I-overexpressing compared to control cells (Figures 5c and d ). Expression of MMP-2, MMP-7 and MMP-9 was generally higher in ST6Gal-Ioverexpressing than in control cells (Figures 5e and f). Moreover, confocal immunofluorescence microscopy showed increased expression and accumulation of β-catenin in the cytoplasm, then β-catenin released into the nucleus (Figure 5g ). Together, this indicates that ST6Gal-I overexpression could upregulate the Wnt signaling pathway in HCC cells.
ST6Gal-I knockdown inhibits Wnt signaling pathway in MHCC97-H cells
Next, we observed that whether the inhibited HCC cell proliferation results from the inhibition of Wnt signaling pathway. We found that the expression of p-GSK-3β, β-catenin and related downstream proteins significantly decreased as a result of reduced ST6Gal-I levels (Figures 6a and b) , while there were no apparent changes in the proteins of Erk1/2 and JNK signaling pathways (Figures 6c and d Figure 7f ). Notably, these proteins were significantly increased in the experimental but not in the control groups at 10 and 24 weeks. Therefore, ST6Gal-I might be directly involved in the tumorigenesis and HCC growth via the Wnt pathway.
DISCUSSION
Cell surface glycosylation, affecting the interactions between proteins, regulates membrane protein organization. 27 Abnormal sialylation was found in many cancers, potentially affecting tumor cell differentiation, adhesiveness and invasion. 28 Here, we examined the expression and localization of ST6Gal-I and sialylation in liver tumor specimens because hepatocytes are known to produce these proteins in large quantities. IHC examination revealed that ST6Gal-I overexpression was higher in HCC tissues of different grades than in to non-tumor liver tissues, and it was secreted into the cytoplasm. Additionally, the IHC results showed that patients with higher ST6Gal-I expression have a lower survival rate. This result is not consistent with that reported by Poon et al., 29 which may be because their sample size was small, yielding inaccurate results, or because they probably focused on terminal patients, in which ST6Gal-I probably has been already released into the peripheral blood as well as body fluid. Thus, it remains to be explored whether the release of ST6Gal-I from the cytosol into peripheral blood corresponds to increased HCC grade. Experiments such as an enzyme-linked immunosorbent assay are needed to verify our current result, and serum ST6Gal-I levels in patients at different liver cancer stages should be tested. Monitoring of HCC progression using patient blood samples has not yet been achieved.
To explore the role of ST6Gal-I in HCC in detail, we modified its expression in Huh-7 and MHCC97-H cell lines in vitro, then aimed to comprehensively elucidate its function during human HCC progression. We found that overexpression of ST6Gal-I enhanced proliferation of HCC cells, increased their migration and invasion in vitro, and promoted cell cycle progression, with knockdown of this protein exerting contrary effects. Notably, ST6Gal-I dysregulation is tightly correlated with tumor metastasis. For the in vivo xenograft experiment, we employed MHCC97-H cells, which have a higher rate of tumorigenicity than Huh-7 cells, and found that ST6Gal-I knockdown via shRNA reduced tumor volume and growth, confirming the function of ST6Gal-I in promoting neoplasm progression. These findings clearly suggest that ST6Gal-I may positively regulate tumor cell attributes such as proliferation, migration and invasion.
Hepatocellular carcinogenesis is a complicated process resulting from multiple molecular events leading to the initiation, promotion and progression of tumors. 30, 31 Zhao et al. 32 reported that sialylation might modulate the invasion and chemosensitivity of HCC, likely through ST6Gal-I or ST8SIA-II regulation of PI3K/Akt signaling. However, to clarify the function of ST6Gal-I in HCC and the associated mechanisms, we examined MAPK, Wnt and PI3K/ Akt pathways. ERK signaling plays an important role in the regulation of proliferation, invasiveness and survival in cancers. 33 However, our results demonstrated that ST6Gal-I upregulation/ downregulation did not affect the phosphorylation levels of Erk and JNK. Furthermore, the tumor-cell-surface glycoprotein, EMMPRIN/CD147 (extracellular matrix metalloproteinase inducer) can induce the secretion of matrix metalloproteinases (MMPs) in the tumor-stroma interaction. MMPs are also considered to play major roles in cell processes such as migration, differentiation, angiogenesis and cancer metastasis. 34 Additionally, the Wnt/βcatenin pathway is also involved in the modulation of tumor angiogenesis and metastasis by affecting the expression of MMP-2 and MMP-9. Our discoveries partly corroborate the supposition that ST6Gal-I can regulate Wnt/β-catenin signaling.
Wnts are N-glycoproteins, and modification of some of them, such as Wnt3a, activates the Wnt/β-catenin canonical pathways. 35, 36 Binding of the Wnt ligand to the receptor Frizzled-7 promotes the nuclear translocation of cytoplasmic β-catenin, which then associates with TCF/LEF transcription factors, and Frizzled receptors are also N-glycosylated. 37 These studies indicate that N-glycoproteins play essential roles in Wnt/β-catenin signaling. Our study revealed that ST6Gal-I upregulation led to a significant increase in cytoplasmic β-catenin and release into the nuclear. Furthermore, western blotting demonstrated that related molecules (p-GSK-3β, β-catenin, cyclin D1, c-Myc and MMPs) were significantly decreased in MHCC97-H/shST6Gal-I cells, but increased in Huh-7/ST6Gal-I cells. These findings indicate that ST6Gal-I regulates the Wnt/β-catenin pathway which might be attributed to the modulation of N-glycosylation of Wnt receptors, and Wnt/β-catenin signaling appears to be involved in ST6Gal-Iinduced malignant transformation of HCC cells. However, the detailed molecular mechanisms how ST6Gal-I modulates the Wnt signaling pathway are still needed to elucidate in further researches.
In conclusion, our data implicate that ST6Gal-I overexpression in human HCC is associated with carcinoma progression and poor clinical prognostic. In addition, ST6Gal-I may accelerate HCC 
MATERIALS AND METHODS
Patients and IHC
ST6Gal-I levels in hepatoma carcinoma and normal hepatic tissues were evaluated by IHC using anti-ST6Gal-I on commercial tissue arrays (Shanghai Zhuo Li Biological Technology, China) as previously described. 38, 39 After antigen retrieval and blocking, the slides were incubated with a rabbit anti-ST6Gal-I primary antibody (1:100; Abcam, Cambridge, UK) overnight at 4°C. Negative control slides were processed in the same manner, without addition of the primary antibody. For detection, diaminobenzidine (DAB) (ZSGB-BIO, Beijing, China) and hematoxylin were used. Two certified pathologists blinded to the clinical data independently assessed ST6Gal-I immunostaining, scoring the results depending on the positive-staining percentages and staining intensity, as follows: (0) 0%, no staining (-); (1) 1-29%, weak positive (+); (2) 30-59%, moderate positive (++); and (3) 460%, intense staining (+++). For statistical analysis, cases were categorized as either negative (no and weak staining) or positive (moderate and intense staining). Pearson's chisquared test was used to assess the association between ST6Gal-I and HCC, to determine its clinical significance.
Cell culture L02 normal liver cells and Huh-7 and MHCC97-H human HCC cells were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). All cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin under standard culture conditions (37°C, 5% CO 2 ), they were tested regularly for mycoplasma contamination in the laboratory.
Vector construction and transfection
Huh-7 cells were transfected with the recombinant pcDNA3.1/ST6Gal-I vector or a control vector. 16 To inhibit ST6Gal-I expression, MHCC97-H cells were transfected with shRNA sequences targeting ST6Gal-I and a negative control vector (shNC) was constructed as described previously. 16, 24 These cells were transfected with a mixture of plasmids and Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) depending on the manufacturer's instructions. To select stably transfected cells, the culture medium was replaced with complete medium containing 800 mg/ml of G418 (Sigma-Aldrich, Darmstadt, Germany) after 48 h. Modified expression was confirmed by qPCR and western blotting. 
Immunofluorescence and confocal microscopy
Cells were plated on slips for 24 h, then these cells were fixed with 4% paraformaldehyde for 30 min, and permeabilized using 0.1% Triton X-100 for 10 min in the dark. They were blocked with 10% bovine serum albumin for 30 min, and incubated overnight with rabbit anti-ST6Gal-I (1:100; Abcam, b77676) and rabbit anti-β-catenin (1:100, Elabscience, ENT0672). A fluorescein-labeled secondary antibody (1:100, Proteintech, SA00006-4) was subsequently incubated with the cells for 1 h at 37°C. Golgi apparatus were identified using a rabbit anti-GM130 antibody (1:50; BD Biosciences, Franklin Lakes, NJ, USA), and 4,6-diamidino-2-phenylindole was used to stain nuclei for 10 min. Fluorescence was observed using a confocal laser-scanning microscope (BD Biosciences).
Soft-agar colony formation assay 0.75% low gelling temperature agarose (Sigma-Aldrich) in complete medium served as the bottom layer, and approximately 4 × 10 4 Huh-7 or 8 × 10 4 MHCC97-H cells suspended in 0.36% agarose in the same medium constituted the top layer in 6-cm dishes. After 4 weeks of incubation, the number of colonies with450 cells in each dish was counted using cellSens software Olympus, Tokyo, Japan).
Flow cytometry
After washing thrice with phosphate-buffered saline (PBS), cells were collected in a tube, and fixed in 70% cold ethanol overnight. Then, they were blocked with 2% bovine serum albumin and incubated on ice for 30 min with 2 μg/mml fluorescein isothiocyanate (FITCc-onjugated) sambucus nigra agglutinin (SNA). After three washes with PBS, flow cytometry was carried out (FCM, Accuri C6 Cytometer; BD Biosciences, San Jose, CA, USA). The cell cycle distribution of Huh-7/MHCC97-H was analyzed by staining with 50 μg/ml propidium iodide. Finally, 1 × 10 4 cells from each sample analyzed by FCM. controlled, air-conditioned, specific pathogen-free facility, and received food and water ad libitum, taking into consideration the guidelines and regulations of the Dalian Medical University Sciences Center Animal Care and Use Committee. The mice were divided into DENA-treated and control groups, those in the former being injected with 1 mg/kg DENA in sterile 15 ml/ kg PBS for 3 weeks, and those in the latter being injected with sterile PBS alone. Then, mice in the DENA group received intraperitone injections of 0.2 ml/kg sterile CCl 4 diluted in sterile olive oil, twice per week for an additional 21 weeks, while control animals were injected intraperitoneally with PBS.
Mice were killed at 0, 2, 4, 8, 9, 10, 16, 18, 20, 22 and 24 weeks after initial treatment to analyze liver neoplasm development. Histopathological examinations to identify liver tumors were performed as described previously. 40 Allocation of the animals and assessment of the outcome were done without blinding.
Statistical analysis
Data were analyzed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA), and every experiment was done three times and the results were shown as the mean s.e. ± s.d. Student's t-test was used to compare two independent groups of data. Differences were considered significant at P-valueso0.05.
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